Multiple System AtrophySTAG-MSANCT03593512
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
A study testing Deep brain stimulation in people with Multiple System Atrophy and Autonomic Failure, run by University of Oxford at 1 site in United Kingdom.
Trial summary
Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease. In the investigators experience, and published evidence shows, that stimulation has effects on the autonomic nervous system. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple System Atrophy, Autonomic Failure, Postural Hypotension
- What is being tested?
- Deep brain stimulation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 9 Sep 2018to 8 Aug 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of MSA with disabling autonomic symptoms (bladder dysfunction and orthostatic symptoms
- UMSARS score of >40
- >6/12 in the autonomic subsection (Q9-12) of the UMSAR scale
- Patient willing and able to give informed consent to involvement in the study.
- Male or female, aged 18 years or over.
- Able to walk unaided (to perform gait analysis)
- Have an anticipated prognosis > 2 years
Who cannot join
- The patient is unwilling to participate or unable to give informed consent.
- The patient has been deemed unfit for stimulator insertion by their healthcare team i.e. surgical contraindications to DBS:
- Bleeding or coagulation disorder
- Not fit for general anaesthetic
- Unable to deal with implanted DBS system (turn on and off and recharging where applicable, although it is acceptable if a carer can do this)
- Untreated anxiety or depression
Show all 9Show fewer
- Unable to undergo MRI (eg. metal implants)
- Subject is currently participating in a clinical investigation that includes an active treatment arm.
- Female who is pregnant - testing will be offered to female patients who are unsure.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
John Radcliffe Hospital
Oxford, Oxfordshire, OX3 9DU
About this study
Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.
In the investigators experience, and published evidence shows, that stimulation has effects on the autonomic nervous system. In patients undergoing therapeutic DBS for a particular subtype of Parkinsonism, Multiple System Atrophy, the further effects on autonomic parameters such as blood pressure and bladder symptoms as well as the originally intended indications (gait and movement disorder) will be investigated. The mechanisms of any effects will also be studied by using a number of techniques such as magnetoencephalography (MEG) and Muscle Sympathetic Nerve Activity (MSNA) recording.
Read more
Key goals are to:
- Demonstrate that stimulation of the peduculopontine nucleus (PPN) improves autonomic function and has an attendant improvement on patients' quality of life
- Investigate the role of the PPN and how it interacts with other brain areas.
This translational strategy will lead to a larger efficacy study of DBS for MSA as well as revolutionizing neural-based treatments in other autonomic disorders such as orthostatic hypotension and pure autonomic failure.
Read the detailed description
AIMS OF THE PROJECT AND IMPORTANCE
Multiple system atrophy (MSA) is a form of Parkinsonism and is a neurodegenerative condition that is characterized by gait and autonomic failure. MSA symptoms are generally poorly responsive to medicines that treat Parkinson's disease (PD), and so symptom control is difficult.
The aim is to assess the effects of deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) on autonomic and gait symptoms to show that it improves quality of life in patients with MSA.
Secondary aims are to assess the effects of stimulation on autonomic parameters (cardiovascular and bladder function) as well as the routine parameters of the movement disorder (gait, freezing and falls, etc).
In addition, there is a mechanistic component of the study looking at both peripheral autonomic activity and brain networks associated with stimulation.
BACKGROUND AND WORK LEADING UP TO THE PROJECT
DBS is a routine treatment for movement disorders such as Parkinson's disease and dystonia. MSA is a 'Parkinsonian' condition similar to PD and is a progressive, incurable, neurodegenerative condition characterized by a combination of Parkinsonism, ataxia, and autonomic failure. Autonomic dysfunction is the presenting feature in half of patients that have Parkinsonism or ataxia predominant MSA.
Whilst DBS is sometimes performed for the treatment of MSA, the primary outcome measure is usually the motor outcome, despite the fact that the autonomic symptoms may be the predominant factor in causing a reduced quality of life. This is because DBS is traditionally used to control motor symptoms and the exploration of its effects on autonomic function are relatively new, and pioneered by our group. The most common complaints caused by autonomic dysfunction in MSA are related to orthostatic hypotension and neurogenic bladder, both of which have been studied by the investigators previously.
Part of the aim of this study is to look at orthostatic BP changes with and without stimulation and see whether these are improved by DBS. Bladder dysfunction includes incontinence and incomplete emptying. These will be investigated using urodynamic testing, with a standard protocol. Other 'autonomic' problems include sleep disorders, exercise intolerance and problems with thermoregulation and sweating. These will be captured using questionnaires.
Regarding the target used for DBS, a well-established target to improve gait and postural abnormalities in PD is the pedunculopontine nucleus (PPN). The investigators have previously demonstrated that the PPN is also a brain area that, when stimulated, improves bladder function in these patients. They have also shown (unpublished data) that PPN stimulation reduces postural fall in BP in a group of PD patients treated primarily for gait and postural problems. It has also been shown that stimulation of a related brain area can improve orthostatic hypotension.
Mechanistic Studies
These are important in order to understand how PPN DBS alters autonomic function. Previously, the investigators have studied the effects of central stimulation of the subthalamic nucleus and periaqueductal grey area (amongst others) on peripheral sympathetic nerve activity. These techniques (muscle sympathetic nerve activity (MSNA)) will be applied in the current study to find out whether PPN DBS alters peripheral sympathetic nervous system activity.
To look at central mechanisms, two techniques will be used. Firstly, diffusion tensor imaging is routinely obtained as part of surgical planning. The hypothesis is that connections from PPN to areas that are part of the central autonomic network are important for influencing autonomic control. By looking at tracts to and from the target area, it will be investigated whether connections to the rostroventrolateral medulla (RVLM) are important for changes in MSNA. The RVLM is an important area that receives feedback from the periphery and is in turn influenced by higher centres.
A second part of the central mechanism study will utilize MEG scanning. The investigators have previously applied this technique to patients who have undergone DBS. The investigator are interested in whether PPN DBS alters cortical activity, both in the insula and anterior cingulate cortices (these are important in autonomic control) and also the motor cortex (important for motor control).
KEY METHODOLOGIES AND TECHNIQUES
Recruitment
Patients will be identified in a movement disorder clinic by a consultant neurologist. If they decide to take part, they will attend to proceed with the consent process and baseline measurements. The pathway for each participant through the study will follow a standardized pattern that is essentially identical to the pathway that current DBS patients for all movement disorder indications go through.
Baseline Assessments
- Questionnaires
- EQ-5D - quality of life questionnaire
- UMSARS - Unified MSA rating scale
- Freezing of Gait (FOG) Questionnaire
- Autonomic questionnaire
- Falls diary
- Neuropsychology assessment. Includes HAD, FLP and MOCA questionnaires and interview.
- MRI scan with DTI. This is routine for surgical planning.
- Gait analysis. Patients will be asked to walk along a special gait flooring which will allow us to obtain specific parameters concerning their gait.
- Urodynamics and Cardiovascular tests
- Urodynamics The 'gold standard' is video urodynamics. This involves urethral catheterisation and insertion of a rectal probe and measurements of detrusor pressures, bladder capacity, reflux, sensory urgency and voiding differences such as rate of urinary flow. Patients who are unwilling to undergo these tests will still fill in voiding diaries and urinary symptom questionnaires that are part of the questionnaires listed above.
- Tilt table tests Patients will undergo continuous ECG monitoring whilst standing upright and then whilst tilted into a lying down position using the tilt table. Changes in heart rate, heart rate variability and blood pressure will be recorded and integrated using our analysis program.
- Ambulatory BP
This involves wearing a blood pressure cuff for 24 hours, which will be timed with the other baseline assessments or, if the participant prefers, this can be done at home.
Subsequent Visits
- Surgery This will follow routine clinical practice. Electrodes will be implanted under general anaesthetic using a standard stereotactic frame. Electrodes will be externalized for a week of clinical testing. During the week of testing, the priority will be to titrate the stimulator for clinical effects. Further gait analysis, tilt table tests and ambulatory BP may be used to inform parameter settings. In addition, we may perform local field potential recordings (recording electrical activity from the electrodes) during these tests. This will give information as to how the PPN is responding to movement and tilt etc. At the end of one week, a second procedure will be performed to insert the implantable pulse generator (the battery). They will return at 6 weeks for stimulator titration only (this is part of routine care).
- 3 month primary outcome follow up
- Questionnaires (section 1 and 2 in baseline assessments above) will be performed as at baseline except the full neuropsychology assessment will not be performed (just the HADS, FLP and MOCA).
- The following tests will be repeated on and off stimulation; i) Urodynamics ii) Tilt table tests iii) Gait analysis
- The participants will attend for a second day and will undergo two further tests ON and OFF stimulation
- Magnetoencephalography (MEG) scan. This records cortical signals ON and OFF stimulation with the aim of demonstrating how PPN suppression or excitation alters cortical activity, especially in the areas important for autonomic and motor control ii. MSNA (microneurography). This technique entails insertion of two very fine needles (30-40microns in diameter) below the knee. The first will record directly from the common peroneal nerve whilst the second will lie subcutaneously as a reference. This is an established technique for measuring peripheral sympathetic activity. Neurograms will be recorded with stimulation ON and then OFF during the same sitting. The aim is to establish whether any changes in autonomic symptomatology are correlated with changes in sympathetic nerve activity, thereby providing a mechanism of action. iii. Sleep EEG studies with varying stimulation ON and OFF in order to investigate the role of the PPN in sleep stages and EEG waveforms.
- Conditions
- Multiple System Atrophy, Autonomic Failure, Postural Hypotension, Bladder, Neurogenic, Gait Disorders, Neurologic
- Being tested
- Deep brain stimulation
- Keywords
- multiple system atrophy, autonomic
- Medical subject headings
- Multiple System Atrophy, Pure Autonomic Failure, Hypotension, Orthostatic, Urinary Bladder, Neurogenic, Gait Disorders, Neurologic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Deep brain stimulationProcedure or surgery
Bilateral deep brain stimulation of the pedunculopontine nucleus
| Study group | Role | What they receive |
|---|---|---|
| PPN DBS | Experimental | All patients will undergo bilateral PPN DBS Receives: Procedure: Deep brain stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
EuroQol 5 Dimension (5 level) score before and after deep brain stimulation
Measurement of quality of life before and after surgery. Results will be given as description of health states - it is not quantitative.
Measured: Through study completion, but on average, over an 8 month period for each patient
Fluency of gait as measured by accelerometry before and after deep brain stimulation
Measurement of gait parameters before and after surgery
Measured: Through study completion, but on average, over an 8 month period for each patient
Modified composite autonomic symptom scale before and after deep brains stimulation
Measurement of autonomic symptomatology before and after surgery - Score from 0-100
Measured: Through study completion, but on average, over an 8 month period for each patient
Change in postural blood pressure change before and after PPN DBS
Measurement of effect on postural blood pressure change before and after surgery
Measured: Through study completion, but on average, over an 8 month period for each patient
Secondary outcomes (4)
Number of Participants With Treatment-Related Adverse Events as Assessed by using approved UK reporting procedure
To assess the safety of PPN DBS on MSA patients by recording adverse events
Measured: Through study completion, 2 years
Muscle sympathetic nerve activity before and after deep brain stimulation
To determine whether or not PPN suppression or excitation alters sympathetic outflow by measuring the activity in autonomic nerves in the leg
Measured: Through study completion, but on average, over an 8 month period for each patient
Cortical magentoencephalography profile with deep brain stimulation on and off
Identification in change of cortical magetic activity with DBS on and off
Measured: 3-6 months after surgery
Physical anatomical white matter connections between the pedunculopontine nucleus and the rest of the central nervous system
To identify the physical anatomical relations of the stimulated region of brain by looking at high resolution structural imaging studies
Measured: Before surgery and 3-6 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2018
- Study start9 Sep 2018
- Primary completion1 Dec 2021
- Study completion8 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple System AtrophyStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Evaluation of symptomatology before and after implantation of DBS electrodes; followed by cross-over of "on" and "off" stimulation
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Collaborators
- Medical Research Council
- Responsible party
- Sponsor
- Investigators
- Alex L Green, FRCS(SN), Principal investigator, University of Oxford
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03593512
- Sponsor's protocol ID
- 13340
- Acronym
- STAG-MSA
- Status last verified
- May 2022
- First submitted
- 22 May 2018
- Last updated
- 2 Nov 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: We are recruiting only 10 patients, so sharing IPD even anonymised, may be identifiable. Decision will be taken when this can be definitively elucidated.
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
- ClinicalTrials.gov ID
- NCT03593512
- Acronym / sponsor ID
- STAG-MSA / 13340
- Conditions
- Multiple System Atrophy, Autonomic Failure, Postural Hypotension, Bladder, Neurogenic, Gait Disorders, Neurologic
- Keywords
- multiple system atrophy, autonomic
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Collaborators
- Medical Research Council
- Study start
- 9 Sep 2018 (actual)
- Primary completion
- 1 Dec 2021 (actual)
- Study completion
- 8 Aug 2022 (actual)
- First posted
- 20 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.
In the investigators experience, and published evidence shows, that stimulation has effects on the autonomic nervous system. In patients undergoing therapeutic DBS for a particular subtype of Parkinsonism, Multiple System Atrophy, the further effects on autonomic parameters such as blood pressure and bladder symptoms as well as the originally intended indications (gait and movement disorder) will be investigated. The mechanisms of any effects will also be studied by using a number of techniques such as magnetoencephalography (MEG) and Muscle Sympathetic Nerve Activity (MSNA) recording.
Key goals are to:
- Demonstrate that stimulation of the peduculopontine nucleus (PPN) improves autonomic function and has an attendant improvement on patients' quality of life
- Investigate the role of the PPN and how it interacts with other brain areas.
This translational strategy will lead to a larger efficacy study of DBS for MSA as well as revolutionizing neural-based treatments in other autonomic disorders such as orthostatic hypotension and pure autonomic failure.
Detailed description
AIMS OF THE PROJECT AND IMPORTANCE
Multiple system atrophy (MSA) is a form of Parkinsonism and is a neurodegenerative condition that is characterized by gait and autonomic failure. MSA symptoms are generally poorly responsive to medicines that treat Parkinson's disease (PD), and so symptom control is difficult.
The aim is to assess the effects of deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) on autonomic and gait symptoms to show that it improves quality of life in patients with MSA.
Secondary aims are to assess the effects of stimulation on autonomic parameters (cardiovascular and bladder function) as well as the routine parameters of the movement disorder (gait, freezing and falls, etc).
In addition, there is a mechanistic component of the study looking at both peripheral autonomic activity and brain networks associated with stimulation.
BACKGROUND AND WORK LEADING UP TO THE PROJECT
DBS is a routine treatment for movement disorders such as Parkinson's disease and dystonia. MSA is a 'Parkinsonian' condition similar to PD and is a progressive, incurable, neurodegenerative condition characterized by a combination of Parkinsonism, ataxia, and autonomic failure. Autonomic dysfunction is the presenting feature in half of patients that have Parkinsonism or ataxia predominant MSA.
Whilst DBS is sometimes performed for the treatment of MSA, the primary outcome measure is usually the motor outcome, despite the fact that the autonomic symptoms may be the predominant factor in causing a reduced quality of life. This is because DBS is traditionally used to control motor symptoms and the exploration of its effects on autonomic function are relatively new, and pioneered by our group. The most common complaints caused by autonomic dysfunction in MSA are related to orthostatic hypotension and neurogenic bladder, both of which have been studied by the investigators previously.
Part of the aim of this study is to look at orthostatic BP changes with and without stimulation and see whether these are improved by DBS. Bladder dysfunction includes incontinence and incomplete emptying. These will be investigated using urodynamic testing, with a standard protocol. Other 'autonomic' problems include sleep disorders, exercise intolerance and problems with thermoregulation and sweating. These will be captured using questionnaires.
Regarding the target used for DBS, a well-established target to improve gait and postural abnormalities in PD is the pedunculopontine nucleus (PPN). The investigators have previously demonstrated that the PPN is also a brain area that, when stimulated, improves bladder function in these patients. They have also shown (unpublished data) that PPN stimulation reduces postural fall in BP in a group of PD patients treated primarily for gait and postural problems. It has also been shown that stimulation of a related brain area can improve orthostatic hypotension.
Mechanistic Studies
These are important in order to understand how PPN DBS alters autonomic function. Previously, the investigators have studied the effects of central stimulation of the subthalamic nucleus and periaqueductal grey area (amongst others) on peripheral sympathetic nerve activity. These techniques (muscle sympathetic nerve activity (MSNA)) will be applied in the current study to find out whether PPN DBS alters peripheral sympathetic nervous system activity.
To look at central mechanisms, two techniques will be used. Firstly, diffusion tensor imaging is routinely obtained as part of surgical planning. The hypothesis is that connections from PPN to areas that are part of the central autonomic network are important for influencing autonomic control. By looking at tracts to and from the target area, it will be investigated whether connections to the rostroventrolateral medulla (RVLM) are important for changes in MSNA. The RVLM is an important area that receives feedback from the periphery and is in turn influenced by higher centres.
A second part of the central mechanism study will utilize MEG scanning. The investigators have previously applied this technique to patients who have undergone DBS. The investigator are interested in whether PPN DBS alters cortical activity, both in the insula and anterior cingulate cortices (these are important in autonomic control) and also the motor cortex (important for motor control).
KEY METHODOLOGIES AND TECHNIQUES
Recruitment
Patients will be identified in a movement disorder clinic by a consultant neurologist. If they decide to take part, they will attend to proceed with the consent process and baseline measurements. The pathway for each participant through the study will follow a standardized pattern that is essentially identical to the pathway that current DBS patients for all movement disorder indications go through.
Baseline Assessments
- Questionnaires
- EQ-5D - quality of life questionnaire
- UMSARS - Unified MSA rating scale
- Freezing of Gait (FOG) Questionnaire
- Autonomic questionnaire
- Falls diary
- Neuropsychology assessment. Includes HAD, FLP and MOCA questionnaires and interview.
- MRI scan with DTI. This is routine for surgical planning.
- Gait analysis. Patients will be asked to walk along a special gait flooring which will allow us to obtain specific parameters concerning their gait.
- Urodynamics and Cardiovascular tests
- Urodynamics The 'gold standard' is video urodynamics. This involves urethral catheterisation and insertion of a rectal probe and measurements of detrusor pressures, bladder capacity, reflux, sensory urgency and voiding differences such as rate of urinary flow. Patients who are unwilling to undergo these tests will still fill in voiding diaries and urinary symptom questionnaires that are part of the questionnaires listed above.
- Tilt table tests Patients will undergo continuous ECG monitoring whilst standing upright and then whilst tilted into a lying down position using the tilt table. Changes in heart rate, heart rate variability and blood pressure will be recorded and integrated using our analysis program.
- Ambulatory BP
This involves wearing a blood pressure cuff for 24 hours, which will be timed with the other baseline assessments or, if the participant prefers, this can be done at home.
Subsequent Visits
- Surgery This will follow routine clinical practice. Electrodes will be implanted under general anaesthetic using a standard stereotactic frame. Electrodes will be externalized for a week of clinical testing. During the week of testing, the priority will be to titrate the stimulator for clinical effects. Further gait analysis, tilt table tests and ambulatory BP may be used to inform parameter settings. In addition, we may perform local field potential recordings (recording electrical activity from the electrodes) during these tests. This will give information as to how the PPN is responding to movement and tilt etc. At the end of one week, a second procedure will be performed to insert the implantable pulse generator (the battery). They will return at 6 weeks for stimulator titration only (this is part of routine care).
- 3 month primary outcome follow up
- Questionnaires (section 1 and 2 in baseline assessments above) will be performed as at baseline except the full neuropsychology assessment will not be performed (just the HADS, FLP and MOCA).
- The following tests will be repeated on and off stimulation; i) Urodynamics ii) Tilt table tests iii) Gait analysis
- The participants will attend for a second day and will undergo two further tests ON and OFF stimulation
- Magnetoencephalography (MEG) scan. This records cortical signals ON and OFF stimulation with the aim of demonstrating how PPN suppression or excitation alters cortical activity, especially in the areas important for autonomic and motor control ii. MSNA (microneurography). This technique entails insertion of two very fine needles (30-40microns in diameter) below the knee. The first will record directly from the common peroneal nerve whilst the second will lie subcutaneously as a reference. This is an established technique for measuring peripheral sympathetic activity. Neurograms will be recorded with stimulation ON and then OFF during the same sitting. The aim is to establish whether any changes in autonomic symptomatology are correlated with changes in sympathetic nerve activity, thereby providing a mechanism of action. iii. Sleep EEG studies with varying stimulation ON and OFF in order to investigate the role of the PPN in sleep stages and EEG waveforms.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Evaluation of symptomatology before and after implantation of DBS electrodes; followed by cross-over of "on" and "off" stimulation
| Arm | Type | Receives |
|---|---|---|
| PPN DBS | Experimental | Procedure: Deep brain stimulationAll patients will undergo bilateral PPN DBS |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Diagnosis of MSA with disabling autonomic symptoms (bladder dysfunction and orthostatic symptoms
- UMSARS score of >40
- >6/12 in the autonomic subsection (Q9-12) of the UMSAR scale
- Patient willing and able to give informed consent to involvement in the study.
- Male or female, aged 18 years or over.
Key exclusion criteria (9 listed)
- The patient is unwilling to participate or unable to give informed consent.
- The patient has been deemed unfit for stimulator insertion by their healthcare team i.e. surgical contraindications to DBS:
- Untreated anxiety or depression
- Unable to undergo MRI (eg. metal implants)
- Subject is currently participating in a clinical investigation that includes an active treatment arm.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Deep brain stimulationBilateral deep brain stimulation of the pedunculopontine nucleus | Procedure or surgery | PPN DBS |
Primary outcome
EuroQol 5 Dimension (5 level) score before and after deep brain stimulation
Time frame: Through study completion, but on average, over an 8 month period for each patient
Measurement of quality of life before and after surgery. Results will be given as description of health states - it is not quantitative.
Fluency of gait as measured by accelerometry before and after deep brain stimulation
Time frame: Through study completion, but on average, over an 8 month period for each patient
Measurement of gait parameters before and after surgery
Modified composite autonomic symptom scale before and after deep brains stimulation
Time frame: Through study completion, but on average, over an 8 month period for each patient
Measurement of autonomic symptomatology before and after surgery - Score from 0-100
Change in postural blood pressure change before and after PPN DBS
Time frame: Through study completion, but on average, over an 8 month period for each patient
Measurement of effect on postural blood pressure change before and after surgery
4 secondary outcomes
Number of Participants With Treatment-Related Adverse Events as Assessed by using approved UK reporting procedure
Time frame: Through study completion, 2 years
Muscle sympathetic nerve activity before and after deep brain stimulation
Time frame: Through study completion, but on average, over an 8 month period for each patient
Cortical magentoencephalography profile with deep brain stimulation on and off
Time frame: 3-6 months after surgery
Physical anatomical white matter connections between the pedunculopontine nucleus and the rest of the central nervous system
Time frame: Before surgery and 3-6 months after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2022.
- Individual participant dataSharing planned: Undecided. We are recruiting only 10 patients, so sharing IPD even anonymised, may be identifiable. Decision will be taken when this can be definitively elucidated.
Related trials for Multiple System Atrophy
RecruitingObservational study
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)
Spinal Muscle Atrophy
RecruitingObservational study
Comparison of Individuals With Primary Ciliary Dyskinesia and Healthy Controls
Primary Ciliary Dyskinesia (PCD)
RecruitingObservational study
Metabolomic Biomarkers of Myotonic Dystrophy
Myotonic Dystrophy Type 1
Active, not recruitingPhase 2
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Multiple System Atrophy
RecruitingPhase 1/2
A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD
Facioscapulohumeral Muscular Dystrophy (FSHD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alex L Green, FRCS(SN) principal investigator
University of Oxford
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Deep brain stimulation in people with Multiple System Atrophy and Autonomic Failure, run by University of Oxford at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
EuroQol 5 Dimension (5 level) score before and after deep brain stimulation (time frame: Through study completion, but on average, over an 8 month period for each patient). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2022.